Format

Send to

Choose Destination
Curr Opin Pharmacol. 2015 Aug;23:82-91. doi: 10.1016/j.coph.2015.05.017. Epub 2015 Jun 18.

PI3K inhibitors in inflammation, autoimmunity and cancer.

Author information

1
Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge CD22 3AT, UK.
2
Refractory Respiratory Inflammation Discovery Performance Unit, Respiratory Therapy Area, GlaxoSmithKline, Stevenage, Hertfordshire, UK.
3
Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge CD22 3AT, UK. Electronic address: klaus.okkenhaug@babraham.ac.uk.

Abstract

The healthy immune system protects against infection and malignant transformation without causing significant damage to host tissues. Immune dysregulation results in diverse pathologies including autoimmune disease, chronic inflammatory disorders, allergies as well as immune deficiencies and cancer. Phosphoinositide 3-kinase (PI3K) signalling has been shown to be a key pathway in the regulation of the immune response and continues to be the focus of intense research. In recent years we have gained detailed understanding of PI3K signalling, and saw the development of potent and highly selective small molecule inhibitors, of which several are currently in clinical trials for the treatment of immune-related disorders and cancer. The role of PI3K signalling in the immune response has been the subject of detailed reviews; here we focus on relevant recent progress in pre-clinical and clinical development of PI3K inhibitors.

PMID:
26093105
PMCID:
PMC4518027
DOI:
10.1016/j.coph.2015.05.017
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center